Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Brain Neoplasms 3Neoplasm Metastasis 2Oligodendroglioma 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Astrocytoma 1

Interventions

Radiotherapy 83Temozolomide 78Filgrastim 34Carboplatin 33Vincristine 29Etoposide 26Cyclophosphamide 25Carmustine 25Irinotecan 23Chemotherapy, Adjuvant 23Cisplatin 21Peripheral Blood Stem Cell Transplantation 20Thiotepa 14Lomustine 14Granulocyte Colony-Stimulating Factor 13Surgical Procedures, Operative 12Procarbazine 12Bevacizumab 11Thalidomide 10O(6)-benzylguanine 10Drug Therapy 10etoposide phosphate 9Methotrexate 9Magnetic Resonance Spectroscopy 9Gene Expression Profiling 9Radiation 8Paclitaxel 8sargramostim 7Ifosfamide 7Everolimus 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Central Nervous System Neoplasms × efaproxiral × Clear all
NCT00005855 2013-06-21

Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
48 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡